Khaberni - Scientists from Stanford Medicine in California have achieved promising results that may change the future of treatment for degenerative arthritis (osteoarthritis), after they succeeded in reactivating worn cartilage in aged mice, potentially paving the way for techniques to repair joints rather than just alleviating pain.
The Advanced Research Projects Agency for Health (ARPA-H) reported that several experimental treatments could help regrow cartilage and bone in people with joint roughness.
The study focused on a protein known as 15-PGDH, which increases with age and is believed to hinder tissue repair processes and increase inflammation within the joint. When researchers inhibited this protein, they noticed that the damaged cartilage began to regain its thickness and elasticity.
Promising Results
In experiments conducted on mice, the treatment showed promising results, where the thickness of the eroded knee cartilage increased, and the ability to walk and move improved, as well as a decrease in pain indicators, and also prevented the progression of roughness after injuries similar to an anterior cruciate ligament tear.
The results were not limited to animals, as the scientists also tested the treatment on human cartilage samples taken from patients who had undergone knee replacement surgery, and encouraging signs of tissue renewal and reduced inflammation were observed.
The same experiment was conducted on samples of human tissue taken from patients who underwent knee replacement surgery. Once again, clear signs of regeneration appeared, where the cartilage became stiffer and signs of inflammation decreased.
Nidhi Bhutani, an orthopedic scientist, says: "The mechanism is truly amazing, and it has changed our view of how tissue regeneration occurs. It is clear that a large group of cells present in the cartilage change their patterns of gene expression."
Why is this important?
This development is important because current treatments for joint roughness mostly focus on easing symptoms only, such as using painkillers, physical therapy, local injections, or resorting to surgical joint replacement in advanced stages.
On the contrary, this new approach aims to address the root cause of the problem, which is the erosion and loss of the cartilage's ability to regenerate, potentially opening the door to more effective and sustainable solutions than just managing pain.
Is the treatment available?
Not yet. The results are still in the pre-clinical trial stages on humans, but researchers have indicated that similar compounds have been tested for safety, which could accelerate the transition to human trials.
In the end, what has happened is not yet a final treatment, but it is one of the most exciting discoveries in the field of joints in years. If human trials succeed in the future, knee or hip replacement might become a less common option than it is today.
